8.59

0.00% 0.00

After Hours: 8.59

Y Mabs Therapeutics Inc (YMAB)

Overview News Price History Option Chain Financials Discussions Forecast

Y Mabs Therapeutics Inc stock is traded at $8.59, with a volume of 522.86K. It is up +0.00% in the last 24 hours and up +0.94% over the past month. Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Previous Close:

$8.59

Open:

$8.59

24h Volume:

522.86K

Relative Volume:

0.62

Market Cap:

$390.32M

Revenue:

$84.82M

Net Income/Loss:

$-21.43M

P/E Ratio:

-17.53

EPS:

-0.49

Net Cash Flow:

$-27.23M

1W Performance:

+0.12%

1M Performance:

+0.94%

6M Performance:

+74.95%

1Y Performance:

-35.12%

1-Day Range:

$8.59

$8.60

1-Week Range:

$8.57

$8.60

52-Week Range:

$3.55

$16.11

Y Mabs Therapeutics Inc Stock (YMAB) Company Profile

Name

Y Mabs Therapeutics Inc

Sector

Healthcare (1152)

Industry

Biotechnology (648)

Phone

646-885-8505

Address

202 CARNEGIE CENTER, PRINCETON, NY

Employee

107

Twitter

Next Earnings Date

2025-03-04

Latest SEC Filings

YMAB's Discussions on Twitter

Compare YMAB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
YMAB Y Mabs Therapeutics Inc	8.59	389.86M	84.82M	-21.43M	-27.23M	-0.49
VRTX Vertex Pharmaceuticals Inc	394.53	99.62B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	465.89	61.52B	2.46B	-319.09M	-52.09M	-2.47
REGN Regeneron Pharmaceuticals Inc	560.00	58.91B	14.21B	4.46B	3.56B	39.68
ARGX Argen X Se Adr	756.38	46.69B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	324.34	34.54B	3.81B	-644.79M	-669.77M	-6.24

Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-22-25	Downgrade	BofA Securities	Neutral → Underperform
Nov-18-24	Initiated	Oppenheimer	Outperform
Aug-16-24	Initiated	Cantor Fitzgerald	Overweight
Jun-28-24	Initiated	Truist	Buy
May-10-23	Upgrade	Wedbush	Neutral → Outperform
Apr-03-23	Downgrade	Guggenheim	Buy → Neutral
Jan-27-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Jan-05-23	Downgrade	Cowen	Outperform → Market Perform
Dec-02-22	Downgrade	BofA Securities	Buy → Neutral
Oct-31-22	Downgrade	JP Morgan	Neutral → Underweight
Oct-31-22	Downgrade	Wedbush	Outperform → Neutral
Jul-06-22	Resumed	Canaccord Genuity	Buy
Jun-24-22	Initiated	BMO Capital Markets	Outperform
Feb-03-22	Resumed	Guggenheim	Buy
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight
Nov-16-21	Downgrade	JP Morgan	Overweight → Neutral
May-07-21	Upgrade	BofA Securities	Neutral → Buy
Apr-23-21	Resumed	Cowen	Outperform
Mar-22-21	Resumed	JP Morgan	Overweight
Jan-15-21	Downgrade	BofA Securities	Buy → Neutral
Nov-09-20	Reiterated	H.C. Wainwright	Buy
May-05-20	Initiated	Barclays	Overweight
May-01-20	Initiated	Janney	Buy
Apr-29-20	Initiated	Morgan Stanley	Equal-Weight
Dec-24-19	Initiated	JP Morgan	Overweight
Nov-20-19	Initiated	Guggenheim	Buy
Sep-04-19	Initiated	Wedbush	Outperform
Apr-01-19	Initiated	H.C. Wainwright	Buy
Oct-16-18	Initiated	BTIG Research	Buy
Oct-16-18	Initiated	BofA/Merrill	Buy

View All

Y Mabs Therapeutics Inc Stock (YMAB) Latest News

Sep 12, 2025

Short Interest in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Decreases By 25.6% - MarketBeat

Sep 12, 2025